公开(公告)号：US11731952B2

公开(公告)日：2023-08-22

申请号：US16633464

申请日：2018-08-29

Applicant: MUSC FOUNDATION FOR RESEARCH DEVELOPMENT ,  LEUKOGENE THERAPEUTICS INCORPORATED

Inventor： Nathan G. Dolloff ,  Reeder M. Robinson ,  Allen B. Reitz ,  Haiyan Bian

IPC: C07C39/38 ,  C07C43/225 ,  C07C61/29 ,  C07C69/708 ,  C07C233/02 ,  C07C233/58 ,  C07D317/70 ,  C07D317/52 ,  C07D319/14 ,  C07D263/52 ,  C07C69/712 ,  A61P35/00 ,  C07C62/32 ,  C07C69/757 ,  C07C235/40 ,  C07C235/34 ,  C07C49/255 ,  C07C59/72 ,  C07C65/11

CPC classification number: C07D317/70 ,  A61P35/00 ,  C07C39/38 ,  C07C43/225 ,  C07C49/255 ,  C07C59/72 ,  C07C61/29 ,  C07C62/32 ,  C07C65/11 ,  C07C69/708 ,  C07C69/712 ,  C07C69/757 ,  C07C233/02 ,  C07C233/58 ,  C07C235/34 ,  C07C235/40 ,  C07D263/52 ,  C07D317/52 ,  C07D319/14 ,  C07C2601/14 ,  C07C2602/08

Abstract: The present invention relates to compounds of formula (I): including any stereochemically isomeric form thereof, or pharmaceutically acceptable salts thereof, for the treatment of, for example, cancer.

公开(公告)号：US20230211157A1

公开(公告)日：2023-07-06

申请号：US18000011

申请日：2021-05-28

Applicant: MUSC Foundation for Research Development

Inventor： Bashar Badran ,  Mark George ,  Doe Jenkins ,  Daniel Cook

IPC: A61N1/36 ,  A61N1/04

CPC classification number: A61N1/36003 ,  A61N1/0456 ,  A61N1/0472 ,  A61N1/36031 ,  A61N1/36034

Abstract: The present invention relates to systems for providing noninvasive cranial nerve stimulation and methods for using the same. The present invention administers therapy through electrodes that are noninvasively attached to one or more of a subject’s cranial nerve. The systems can be used to enhancing rehabilitation and recovery by improving neuroplasticity and coupling muscle training with feedback.

公开(公告)号：US20230190930A1

公开(公告)日：2023-06-22

申请号：US17839029

申请日：2022-06-13

Applicant: MUSC Foundation for Research Development

Inventor： Daniel FERNANDES ,  Laura Schwartz ,  Natalie Sutkowski ,  Brian Hoel ,  Semyon Rubinchik

IPC: A61K39/395 ,  C07K16/18 ,  A61P35/00

CPC classification number: A61K39/395 ,  C07K16/18 ,  A61K39/3955 ,  A61P35/00 ,  C07K16/3015

Abstract: The present disclosure provides anti-nucleolin antibodies, methods of producing anti-nucleolin antibodies, and cells producing anti-nucleolin antibodies. Also provided are methods of using anti-nucleolin antibodies in treating malignant and non-malignant diseases.

公开(公告)号：US20230025360A1

公开(公告)日：2023-01-26

申请号：US17817125

申请日：2022-08-03

Applicant: MUSC Foundation for Research Development

Inventor： Shikhar Mehrotra ,  Pravin Kesarwani ,  Shilpak Chatterjee

IPC: A61K35/17 ,  A61P35/00 ,  A61K31/381 ,  A61K31/401 ,  A61K38/06 ,  A61K38/20 ,  A61K38/43 ,  C12N5/0783

Abstract: The present invention relates to an adoptive T cell therapy using cells generated by genetically or biochemically reprogramming T cells to produce T memory stem cells (Tscm) that persist longer in vivo and are superior anti-tumor effector cells.

公开(公告)号：US11511028B2

公开(公告)日：2022-11-29

申请号：US16404726

申请日：2019-05-06

Applicant: MUSC Foundation for Research Development

Inventor： Dieter Haemmerich ,  Anjan Motamarry

IPC: A61M1/34 ,  A61K41/00 ,  A61M1/36 ,  A61K49/00

Abstract: A system for reducing toxicity from intravascular triggered drug delivery includes a chamber comprising an inflow port, an outflow port, and a filter positioned upstream of the outflow port. A trigger module is configured to trigger the release of a drug from an intravascular triggered drug delivery system present in blood in the chamber. A method for reducing toxicity from intravascular triggered drug delivery includes the steps of removing blood comprising an intravascular triggered drug delivery system from a patient's vascular system and delivering the blood to a chamber, applying a trigger to the blood to release a drug from the intravascular triggered drug delivery system, filtering the drug from the blood, and returning the filtered blood to the patient.

公开(公告)号：US20220324998A1

公开(公告)日：2022-10-13

申请号：US17620395

申请日：2020-06-18

Applicant: MUSC Foundation for Research Development ,  New York University ,  The United States Government as Represented by the Department of Veterans Affairs

Inventor： John O'Bryan ,  Shohei Koide ,  Akiko Koide

IPC: C07K16/32 ,  A61K39/395 ,  A61P35/00 ,  G01N33/574

Abstract: The invention provides compositions and methods for binding Ras in a nucleotide free state (apo RAS) and inhibiting Ras signaling. In one embodiment, the invention provides monobodies that specifically bind apo RAS and methods of use. Thus, in diseases and conditions where a reduction of Ras signaling is beneficial, such inhibitory compositions act as therapeutics.

公开(公告)号：US20220296889A1

公开(公告)日：2022-09-22

申请号：US17619950

申请日：2020-06-29

Applicant: MUSC Foundation for Research Development

Inventor： Bashar Badran ,  Mark S. George

IPC: A61N1/32 ,  A61N1/04 ,  A61N1/36

Abstract: A system for neurorehabilitation is disclosed that includes a motion detector configured to generate a motion detection feedback signal, a transcutaneous auricular vagus nerve stimulation module, and a controller configured to receive the motion detection feedback signal and send a stimulation signal to the transcutaneous auricular vagus nerve stimulation module based on the motion detection feedback signal meeting a minimum threshold criteria. A method for neurorehabilitation is disclosed that includes the steps of detecting patient motor activity, determining if the detected patient motor activity meets a minimum threshold criteria, and stimulating a vagus nerve through transcutaneous auricular vagus nerve stimulation if the minimum threshold criteria is met.

公开(公告)号：US11446111B2

公开(公告)日：2022-09-20

申请号：US16496495

申请日：2018-03-19

Applicant: MUSC Foundation for Research Development

Inventor： Raymond Turner ,  Mark E. Semler ,  Aquilla Turk ,  Alex Spiotta ,  Imran Chaudry

IPC: A61B90/10

Abstract: A cranial anchor system configured to attach to an opening in a cranium includes an anchor member. The anchor member has a middle anchor portion and a lower anchor portion coupled to and disposed in a downward direction relative to the middle anchor portion. The lower anchor portion has a plurality of contact members, each of which have a leg that extends at least partially in the downward direction, a tab connected to the leg, and a rib disposed between the leg and the tab. The system further includes an outer sheath and an inner sheath disposed within the outer sheath and slidable relative to the outer sheath.

公开(公告)号：US20220119344A1

公开(公告)日：2022-04-21

申请号：US16956871

申请日：2020-06-04

Applicant: MUSC FOUNDATION FOR RESEARCH DEVELOPMENT

Inventor： Patrick M. WOSTER ,  Joy E. KIRKPATRICK

IPC: C07C235/38

Abstract: The invention relates to KDM4B inhibitors, compositions comprising an effective amount of KDM4B inhibitors and methods for treating inflammatory diseases and disorders.

公开(公告)号：US11214805B2

公开(公告)日：2022-01-04

申请号：US16548945

申请日：2019-08-23

Applicant: MUSC FOUNDATION FOR RESEARCH DEVELOPMENT

Inventor： Ann-Marie Broome ,  Suraj Dixit ,  Satish Nadig ,  Carl Atkinson

IPC: A61K39/395 ,  C12N15/117 ,  A61K47/62 ,  A61K47/69 ,  A61K31/395 ,  A61K38/20 ,  C12N15/11 ,  A61K31/365 ,  A61K31/436 ,  A61K31/713 ,  A61K35/17 ,  A61K38/13 ,  A61K38/17 ,  A61K35/12

Abstract: Disclosed is a nanocarrier-containing immunosuppressive agent that is targeted to C3 breakdown products, integrin, or a combination thereof, to reduce the deleterious systemic effects of the immunosuppressive agent. Also disclosed is a method for suppressing an allo-immune response in a subject, such as one that can occur after an allograft transplantation.